Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577114 | 1.00 | JAK1 (0.48) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL31485228 | 1.00 | JAK1 (0.48) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL14852445 | 0.87 | MAPT (0.41) | HDAC1HSD11B1USP30ALDH1A1LMNA | |
| SCHEMBL24595762 | 0.87 | GPR119 (0.45) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL29707371 | 0.87 | GPR119 (0.45) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL21457817 | 0.86 | JAK1 (0.48) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL29577318 | 0.86 | JAK1 (0.48) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL16824902 | 0.84 | JAK1 (0.46) | JAK1HDAC1HSD11B1CHRM2CHRM1 | |
| SCHEMBL27405003 | 0.82 | HDAC1 (0.49) | HDAC1GPR119USP30ALDH1A1LMNA | |
| SCHEMBL27405008 | 0.82 | HDAC1 (0.49) | HDAC1GPR119USP30ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250082-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-109071561-B | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | 福马治疗股份有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113614087-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-112724144-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3414251-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139779-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP25, USP28, USP30 | JAK1 390/4885HDAC1 197/4885HSD11B1 3627/4885 |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | JAK1 390/4885HDAC1 197/4885HSD11B1 3627/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | JAK1 652/4885HDAC1 1831/4885HSD11B1 2240/4885 |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | JAK1 390/4885HDAC1 197/4885HSD11B1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.